Following Laekna (2105.HK) & Eli Lilly and Company?
Get the free weekly contract digest
The latest new contracts, like Laekna (2105.HK) & Eli Lilly and Company’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Laekna Announces Clinical Collaboration with Lilly to Develop LAE102 Monoclonal Antibody for the Treatment of Obesity
Nov 20, 2024•over 1 year ago
Contract Type
partnership
Los AngelesBiotechnologyHealth CareDescription
Laekna, Inc. has announced a clinical collaboration with Eli Lilly and Company to develop LAE102, an ActRIIA antagonistic mAb as a novel treatment for obesity. The collaboration will focus on the clinical evaluation of LAE102, which may have potential as a first-in-class therapy in this disease area.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months